Long-Term Follow-Up of Drug-Eluting Stents Placed in the Setting of ST-Segment Elevation Myocardial Infarction⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.  by Ziada, Khaled M. et al.
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ong-Term Follow-Up of
rug-Eluting Stents Placed in
he Setting of ST-Segment
levation Myocardial Infarction*
haled M. Ziada, MD,† Richard Charnigo, PHD,†‡
avid J. Moliterno, MD†
exington, Kentucky
he approval for marketing and distribution of drug-eluting
tents (DES) by the U.S. Food and Drug Administration
as based on seminal trials that primarily included stable
atients with noncomplex coronary artery lesions. Not
urprisingly, given the marked reduction in the need for
epeat target vessel revascularization (TVR) with DES
ompared with bare-metal stents (BMS), interventional
ardiologists quickly expanded the use of DES to “off-label”
ubsets of lesions and patients, including those presenting
ith ST-segment elevation myocardial infarction.
See pages 14, 24, and 30
As with other off-label uses of DES, large registries
emonstrated overall safety and efficacy of DES for primary
ercutaneous coronary intervention (PCI), but questions
merged regarding selection bias, sample size, and late and
ery-late stent thrombosis (ST) in these registries (1,2).
andomized trials and meta-analyses (3–10) eventually
roduced more robust data that confirmed the value of DES
ver BMS in reducing TVR following primary PCI. None-
heless, most of these trials were small, ST events were rare,
nd initial reports did not address late and very-late ST
ecause protocol-mandated follow-up was usually limited to
2 months or less. To further heighten anxiety about DES
se in primary PCI, observational data demonstrated very-
ate ST to occur at a higher frequency among patients
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the †Gill Heart Institute, Division of Cardiovascular Medicine, University of
entucky, Lexington, Kentucky; and the ‡Department of Statistics, University of
entucky, Lexington, Kentucky. Drs. Ziada and Moliterno have received past
onsultancy honoraria from Boston Scientific Inc. and Abbott Vascular Inc., manu-a
acturers of bare-metal and drug-eluting stents. All other authors have reported that
hey have no relationships to disclose.ndergoing PCI for STEMI, compared with those present-
ng for elective PCI (11,12).
In this issue of JACC: Cardiovascular Interventions,
articles address these concerns with datasets including
articularly long follow-up. Two reports present long-term
esults from randomized trials comparing DES to BMS: the
YPHOON (Trial to Assess the Use of the Cypher Stent
n Acute Myocardial Infarction Treated With Angioplasty)
nd PASSION (Paclitaxel Eluting Stent Versus Conven-
ional Stent in ST-Segment Elevation Myocardial Infarc-
ion) trials (13,14). Whereas PASSION had almost com-
lete 5-year follow-up, TYPHOON investigators were only
ble to follow 70% of patients for 4 years. To address this
imitation, the TYPHOON investigators used a novel
tatistical technique, a so-called tipping point analysis, to
stimate the effect of the missing data on their findings.
ther distinctions include TYPHOON’s testing of
irolimus-eluting stents (SES) versus BMS with protocol-
andated angiographic follow-up, whereas, PASSION
ompared paclitaxel-eluting stents (PES) with BMS, and
ollow-up angiograms were performed only if clinically
ndicated. The third paper, by Brodie et al. (15), describes a
arge single-center registry with prospectively collected data
n all patients undergoing primary PCI over more than a
ecade. This registry included patients receiving PES, SES,
nd second-generation DES. Follow-up was clinical (not
ngiographic) and included almost all patients. This report
ontains a formal landmark analysis of outcomes after the
rst year, which is of particular interest to the readers
ooking for evidence for or against very-late stent thrombo-
is. The conclusions of the 3 reports have overall consistency
ut with the balance between risk and benefit of DES
arying to some degree among them. To add to the
onsideration of these articles, 5 other randomized trials
ave recently reported their long-term follow-up of DES
se among ST-segment elevation myocardial infarction
atients (6,16–19). The main characteristics of all 7 ran-
omized trials are summarized in Table 1, and their main
utcomes are detailed in Table 2, along with a random-
ffects meta-analysis.
So with all these data, what have we learned? First, all of
hese studies suggest that DES use has no negative (or
ositive) impact on mortality, which should be reassuring.
n the registry report by Brodie et al. (15), there is a clear
ignal for more reinfarctions with DES after the first year,
lthough this did not translate into a mortality difference at
early 5 years of follow-up.
Second, DES use results in a reduction in TVR by almost
0% (Table 2), which is a striking yet almost-taken-for-
ranted finding. In the trials that did not show such a clear
dvantage for DES or in which that advantage dissipated
ith longer follow-up, explanations are not clear. A possi-
ility is that the advantage of DES in reducing TVR is more
pparent when angiographic follow-up is mandated, as
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40pposed to being ischemia-driven. Other explanations may
elate to the type of DES used. The lack of reduction in
VR in the DES arm of the PASSION trial may be related
o a higher late lumen loss with PES, compared with a
elatively lower late loss following SES use. A similar
bservation can be inferred from the data of Kukreja et al.
1), which exhibited no clear difference in TVR rates
etween DES (mostly PES) and BMS after 3 years.
Third, and most importantly, the randomized trials provide
o evidence of an increased incidence of ST following use of
ES versus BMS in primary PCI. As previously discussed, the
ncidence of ST is higher among primary PCI patients, but the
verall low frequency of these events makes it unlikely for any
f the randomized trials alone to show a significant difference
etween the stent groups. By considering all 7 randomized
rials (6,13,14,16–19) and including more than 3,000 patients
ollowed for at least 3 years (Table 1), a random-effects
eta-analysis results in an estimated odds ratio for ST with
ES versus BMS of 0.99 (95% confidence interval: 0.68 to
.45) (Table 2). This neutral odds ratio estimate strongly
Table 1. Main Characteristics of Randomized Trials of DES Versus BMS in
Study (Ref. #)
Sample Size
(DES/BMS) Type of DES
DEDICATION (16) 313/313 SES, PES and ZES
PASEO (6) 180/90 SES and PES
STRATEGY (19) 87/88 SES
SESAMI (17) 160/160 SES
MISSION (18) 152/152 SES
TYPHOON (13) 355/357 SES
PASSION (14) 310/309 PES
*100% for survival status; 91% for other clinical events.
BMS bare-metal stent(s); DEDICATION Drug Elution and Distal Protection in Acute Myoca
Evaluate the Efficacy of Drug-Eluting Stents versus Bare-Metal Stents for the Treatment of Acute
Angioplasty randomized trial; PASSION  Paclitaxel Eluting Stent Versus Conventional Stent in S
Sirolimus-Eluting Stent Versus Bare-Metal Stent inAcuteMyocardial Infarction trial; STRATEGY Sing
Infarction trial; TYPHOON Trial to Assess the Use of the Cypher Sirolimus-Eluting Coronary Stent
Table 2. Outcomes of Randomized Trials of DES Versus BMS in Primary PC
Study (Ref. #)
Death (%)
DES BMS
Estimated OR
(95% CI) p Value DES
DEDICATION (16) 10.5 6.4 1.73 (0.97–3.08) 0.06 8.9
PASEO (6) 8.3 12.2 0.65 (0.29–1.49) 0.31 6.1
STRATEGY (19) 18.4 15.9 1.19 (0.54–2.62) 0.66 10.3
SESAMI (17) 3.2 5.0 0.61 (0.20–1.92) 0.40 8.3
MISSION (18) 4.4 6.6 0.69 (0.25–1.85) 0.46 8.9
TYPHOON† (13) 4.0 6.6 0.61 (0.27–1.36) 0.23 11.9
PASSION (14) 8.9 11.5 0.75 (0.45–1.27) 0.29 7.7
Meta-analysis 0.89 (0.64–1.24)
*Definitions of ST varied among studies. The ARC definition was used for all except PASEO. DEDICA
reported definite/probable/possible. †Analysis based on actual data (501 patients).ARC Academic Research Consortium; CI confidence interval; OR odds ratio; ST stent thrombuggests that the use of DES does not have an impact on ST
n this patient population. The wide confidence interval
hough is a reminder of the overall paucity of ST events, even
n a 3,000-patient meta-analysis.
The data presented by Brodie et al. (15) tell a somewhat
ifferent story. This registry documents a disturbing signal
f increased late and very-late ST with DES, which is only
pparent in a landmark analysis performed for events
ccurring after 1 year. These findings echo those of other
ong-term registries, in which very-late ST after primary
CI is only noted with DES (1,11). As is well-known,
andomized trial and registry data differ, mainly in the types
f patients included. Randomized trials generally recruit
atients with less comorbidity and who are more likely to
omply with study protocols (including long-term medical
herapy), whereas registries include “all-comers” or “real-
ife” patients with complexities such as those who have
ultiple comorbidities, are noncompliant, or cannot afford
lose follow-up and long-term therapy. However, the asso-
iation between adherence to dual antiplatelet therapy and
ry PCI With Long-Term Follow-Up (>3 Years)
Angiographic
Follow-Up
Follow-Up
(Months)
Completeness of
Follow-Up
No Median 42 100%
No Mean 41 100%
No 60 100%
No 36 98%
Yes 36 91%*
Yes 48 70%
No 60 98%
arction trial; DES drug-eluting stent(s); MISSION A Prospective Randomised Controlled Trial to
dial Infarction; PASEO  Paclitaxel- or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary
ent Elevation Myocardial Infarction trial; PCI  percutaneous coronary intervention; SESAMI 
-Dose Bolus Tirofiban andSirolimus-Eluting Stent vs. Abciximab andBare-Metal Stent inMyocardial
Myocardial Infarction Treated With Balloon Angioplasty; ZES zotarolimus-eluting stent(s).
Long-Term Follow-Up (>3 Years)
TVR (%) ST (%)*
S
Estimated OR
(95% CI) p Value DES BMS
Estimated OR
(95% CI) p Value
8 0.40 (0.25–0.64) 0.01 2.9 3.2 0.90 (0.36–2.24) 0.82
1 0.24 (0.11–0.54) 0.01 1.1 2.2 0.49 (0.07–3.57) 0.48
1 0.33 (0.14–0.75) 0.01 6.9 7.9 0.86 (0.28–2.66) 0.79
0 0.46 (0.23–0.92) 0.03 5.1 5.1 1.00 (0.37–2.73) 1.00
8 0.54 (0.27–1.09) 0.09 3.1 2.0 1.69 (0.40–7.20) 0.48
5 0.49 (0.30–0.80) 0.01 5.3 5.5 0.92 (0.42–2.00) 0.83
5 0.73 (0.42–1.26) 0.26 4.2 3.4 1.19 (0.52–2.69) 0.68
0.46 (0.36–0.58) 0.99 (0.68–1.45)
ISSION, TYPHOON, and PASSION reported definite/probable ST, whereas STRATEGY and SESAMIPrima
rdial Inf
Myocar
T-Segm
leHighI With
BM
19.
21.
26.
16.
15.
21.
10.
TION, Mosis; TVR target vessel revascularization; other abbreviations as in Table 1.
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41ate or very-late ST events is not clear and is probably less
elevant as many patients will be off dual therapy after 12
onths.
In conclusion, the jury may still be out on the use of DES
or all-comers undergoing primary PCI. Randomized trials
ave demonstrated significant reduction in TVR and no
ignificant increase in ST or mortality, now even at 3 to 5
ears. The multiplicity of randomized trials underpinning
hese conclusions should reassure the interventional com-
unity and authors of future practice guideline documents.
he signal toward increased ST in long-term registries
aises concern about the use of DES in patients who are not
ypical of randomized trial cohorts. The number of ST
vents remains small and difficult to tackle statistically.
uestions and developments that may influence future
irections are many. Examples include the duration of
ntiplatelet therapy, the role of second-generation P2Y12
nhibitors with their well-established improved efficacy, the
ole of platelet function and genetic testing that can better
efine patient subgroups at risk, and last but not least, the
alue of newer-generation DES designs. The completion of
he DAPT (Dual Anti-Platelet Therapy) Registry (20),
ith its planned very large number of patients and very
ong-term follow-up will provide more insight into DES-
ssociated stent thrombosis.
eprint requests and correspondence: Dr. Khaled M. Ziada,
ivision of Cardiovascular Medicine, University of Kentucky, 900
outh Limestone, 317 Wethington Building, Lexington, Ken-
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